Keep it to one recall a week. Is that too much to ask Johnson & Johnson (NYSE: JNJ)?

Instead, the health-care giant is out with its second. Earlier this week, I reported about a manufacturing problem with its contact lenses, and now Johnson & Johnson is recalling two hip- replacement devices that seem to fail at a higher-than-expected rate. And that's on top of the ongoing problems with its over-the-counter medications.

The cost of this recall won't be that huge. Johnson & Johnson had been phasing out the hip-replacement devices, so the hit to sales won't be that great. The company has agreed to pay for the surgeries of patients who will need replacements because of the recall.

Then there are the potential costs from lawsuits if plaintiffs seek damages for pain and suffering. This isn't like the children's medicines that were recalled earlier in the year when the drugs hadn't been reported to cause any serious harm. Jurors are likely to be sympathetic to frail grandmas who have to go through a seemingly needless additional surgery.

And then, of course, there's the ongoing problem of tarnishing the Johnson & Johnson name. Stryker (NYSE: SYK), Zimmer (NYSE: ZMH), and Smith & Nephew (NYSE: SNN), which all sell implants, stand to gain from this recall. The big question is how many more issues is it going to take before doctors start shunning any Johnson & Johnson product for fear that there might be a problem? Will doctors start recommending Abbott Labs' (NYSE: ABT) Humira or Pfizer (NYSE: PFE) and Amgen's (Nasdaq: AMGN) Enbrel over Johnson & Johnson's (NYSE: JNJ) Remicade simply because it's made by a company with a tainted name?

Whether we've reached that point, I don't know. Let's just hope I'm not writing about another recall next week.

Bryan Hinmon wonders if this stock is a land mine.

Johnson & Johnson is a Motley Fool Income Investor selection. Motley Fool Options has recommended a diagonal call position on Johnson & Johnson. Pfizer and Stryker are Inside Value picks. Try any of our Foolish newsletter services free for 30 days

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.